Patents by Inventor Raymond G. Goodwin
Raymond G. Goodwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8133976Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.Type: GrantFiled: November 6, 2009Date of Patent: March 13, 2012Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Wanwan S. Din
-
Patent number: 7972812Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: GrantFiled: May 13, 2010Date of Patent: July 5, 2011Assignee: Immunex CorporationInventors: Steven R. Wiley, Raymond G. Goodwin
-
Publication number: 20100323399Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: ApplicationFiled: May 13, 2010Publication date: December 23, 2010Applicant: IMMUNEX CORPORATIONInventors: Steven R. Wiley, Raymond G. Goodwin
-
Publication number: 20100196404Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.Type: ApplicationFiled: November 6, 2009Publication date: August 5, 2010Applicant: IMMUNEX CORPORATIONInventors: RAYMOND G. GOODWIN, WANWAN S. DIN
-
Patent number: 7736637Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: GrantFiled: August 21, 2008Date of Patent: June 15, 2010Assignee: Immunex CorporationInventors: Steven R. Wiley, Raymond G. Goodwin
-
Publication number: 20090270592Abstract: Purified protein preparations comprising tumor necrosis factor are disclosed.Type: ApplicationFiled: October 24, 2007Publication date: October 29, 2009Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
-
Publication number: 20090264349Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: ApplicationFiled: May 9, 2007Publication date: October 22, 2009Applicant: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Publication number: 20090118186Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: ApplicationFiled: August 21, 2008Publication date: May 7, 2009Applicant: IMMUNEX CORPORATIONInventors: Steven R. Wiley, Raymond G. Goodwin
-
Publication number: 20090081700Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.Type: ApplicationFiled: July 23, 2008Publication date: March 26, 2009Applicant: Immunex CorporationInventors: Raymond G. Goodwin, Wanwan S. Din
-
Patent number: 7459528Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.Type: GrantFiled: October 28, 2005Date of Patent: December 2, 2008Assignee: Immunex CorporationInventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
-
Patent number: 7416877Abstract: Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: GrantFiled: October 3, 1997Date of Patent: August 26, 2008Assignee: Immunex CorporationInventors: Mariapia A. Degli-Esposti Rankin, Raymond G. Goodwin
-
Patent number: 7232660Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: October 2, 2003Date of Patent: June 19, 2007Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage
-
Patent number: 7211259Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: August 5, 1997Date of Patent: May 1, 2007Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith
-
Patent number: 7138500Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: September 10, 1998Date of Patent: November 21, 2006Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
-
Patent number: 7057022Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.Type: GrantFiled: April 23, 2003Date of Patent: June 6, 2006Assignee: Immunex CorporationInventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
-
Patent number: 6852486Abstract: A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.Type: GrantFiled: July 3, 2002Date of Patent: February 8, 2005Assignee: Immunex Corp.Inventors: Craig A. Smith, Raymond G. Goodwin
-
Publication number: 20040241758Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: ApplicationFiled: October 2, 2003Publication date: December 2, 2004Applicant: IMMUNEX CORPORATIONInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Publication number: 20040180826Abstract: Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: ApplicationFiled: December 23, 2003Publication date: September 16, 2004Applicant: Immunex CorporationInventors: Mariapia A. Degli-Esposti Rankin, Raymond G. Goodwin
-
Publication number: 20040052788Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: ApplicationFiled: September 2, 2003Publication date: March 18, 2004Applicant: IMMUNEX CORPORATIONInventors: Steven R. Wiley, Raymond G. Goodwin
-
Patent number: 6667039Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplasdic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: July 28, 2000Date of Patent: December 23, 2003Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
